The poor efficacy of MEK single drug also results from tumor drug resistance, and the current drug resistance mechanism includes reactivation of MAPK level pathway; up-regulation of other parallel pathways, such as PI3K, signal transducer and activator of transcription (STAT) and Hippo signaling pathway 68-70; and transformation of cell phenotypic 71. This evidence concerns the gene MAP2K7 and neoplasm.